Immutep Reports Exposure-Dependent Inhibition of T-Cell-Driven Responses
BiotechnologyImmutep’s IMP761 showed significant, exposure-dependent suppression of T-cell responses in Phase I, with no serious or severe adverse events.Imelda CottonJournalist · 2 min readIn this storyIMMIn…

Immutep’s IMP761 showed significant, exposure-dependent suppression of T-cell responses in Phase I, with no serious or severe adverse events.
Imelda CottonJournalist · 2 min readIn this storyIMMIn briefAt-a-glance3 takeaways- 01IMP761 was well tolerated at all seven doses.
- 02A single infusion dose-dependently suppressed T-cell responses.
- 03Multiple-dose data due next year to guide Phase II.
Clinical-stage biotechnology company Immutep (ASX: IMM) has released positive data from a Phase I study of first-in-class lymphocyte activation gene-3 (LAG-3) agonist antibody IMP761 aimed at treating autoimmune diseases by targeting their root cause.
The randomised placebo-controlled, double-blind, first-in-human study conducted by the Centre for Human Drug Research in the Netherlands showed the drug was well-tolerated across a cohort of healthy volunteers at all seven dose levels (0.03 milligrams per kilogram to 14mg/kg), with no serious or severe adverse events reported.
Volunteers were immunised three times with keyhole limpet haemocyanin before receiving small injections of the glycoprotein into the dermis to produce a measurable T-cell-driven local intra-dermal reaction.
The model is seen as the standard way of testing whether a drug can dampen a strong tissue T-cell-driven immune response to a foreign antigen, potentially enabling it to silence T-cell responses to self-peptides in patients with autoimmunity.
Statistically Significant Results
Chief scientific officer Dr Frédéric Triebel said the new data built on positive first-in-human results presented at this year’s European Alliance of Associations for Rheumatology congress in London by demonstrating statistically significant, exposure-dependent suppression of immune responses after a single IMP761 infusion.
“These results derived from a large double-blinded trial clearly show the immuno-suppressive effect of IMP761 on a strong antigen-driven T-cell response in tissues, without safety concerns,” he said.
“After this challenging proof-of-concept in healthy participants, we are confident that direct T-cell receptor inhibition through LAG-3 agonism opens a new frontier in the treatment of autoimmune patients where the root cause of the disease is driven by the overreaction of a few weak-affinity self-peptidereactive pathogenic T-cells that should be controlled by IMP761.”
Results from the multiple ascending dose portion of the Phase I study are scheduled for release in the new year to inform dose selection for a future Phase II program.
AdvertisementSuppressing Immune Response
Immutep is pioneering the advancement of therapeutics related to LAG-3 and its diversified product portfolio harnesses the gene’s ability to stimulate or suppress the immune response.
Lead candidate IMP761 is an agonist IgG4 monoclonal antibody designed to enhance LAG-3’s natural inhibitory function on chronically activated, self-reactive T-cells that drive many autoimmune diseases.
It is designed to selectively target activated T-cells at sites of inflammation, with the aim of reducing pathological immune responses while preserving systemic immune function.
IMP761 is believed to be the only LAG-3 agonist antibody currently in clinical development.
The latest results came as part of a late-breaking abstract from ACR Convergence 2026 in Florida, the annual scientific meeting of the American College of Rheumatology.
Subscribe · daily wireGet the wire before the market opens.
The ASX small-cap stories that matter, filed before 9am AEST. Curated by the Small Caps desk.
Join 100,000+ investors. Unsubscribe anytime.About the authorImelda Cotton
JournalistView all articlesMore like this
View all latestFigures reflect the source report and its stated period. This article is for information and is not investment advice.



